8th International

China Pharmaceutical
R&D Summit
Harnessing the Best of East and West to Fuel Drug Development
20 – 23 May 2013 | Grand Hyatt Shanghai, China
2013 KEYNOTE SPEAKERS
2013 WHY THIS IS A
Alan Sheppard Jim O’Mara MUST-ATTEND EVENT:
Principal, Global Generics, Vice President Corporate
Thought Leadership, Development, • A fresh speaker panel and new case
IMS Health, UK Ironwood Pharmaceuticals, studies, ‘of the moment’
USA collaborations such as Ironwood-
AstraZeneca and NeuroVive-Sihuan
Barry Bernstein MD Ka-Kit Hui, MD, FACP • Key established and emerging
Divisional Vice President, Professor, Founder & Director, domestic companies including
Infectious Disease Center for East-West Chipscreen, SK Biopharma, Genor,
Development, Global Medicine, Department of
Pharmaceutical Research Medicine, UCLA, USA Hua Medicine and Shanghai
and Development, Genomics
AbbVie, USA
• Insights from leading investment
New Speakers at China Pharma R&D 2013 Include: experts including OrbiMed, FIL
Peter Peizhi Luo, Chief Executive Officer, Adagene Inc., China
Capital Management, Sequoia
Cezary Statuch, MD, Vice President, Head of China R&D, Bristol-Myers Squibb, China
Capital, KPCB and Goldman Sachs
Bon Chul Brian Ku, General Manager, SK Biopharm (Shanghai), China • In-depth & interactive formats:
Robert Braithwaite, CEO, Luqa Pharmaceuticals, China Pharma Fireside Chat, CxO Panel and
Zhi-Qiang Ning, MD, PhD, Cofounder, VP R&D, Shenzhen Chipscreen Biosciences Ltd, China Industry Strategizing Session
Pui-Kwong Chan, PhD, Professor, Department of Pharmacology, Baylor College of Medicine, USA
Dr Zheng Li, General Manager, Lundbeck Research, China
Zhen Zhang, Associate Director, Analytical and Bioanalytical Development, Bristol-Myers Squibb, China
Mikael Brönnegård, MD, PhD, Associate Professor, and Chief Executive Officer, NeuroVive Pharmaceutical AB, Sweden
Rahim Rezaie, Research Fellow, Rotman School of Management, University of Toronto and Asia Pacific Foundation of Canada (Vancouver), Canada
Yajiong Xue, PhD, Director, Center for Healthcare Management Systems, Associate Professor of MIS, College of Business, East Carolina University, USA
Yu-Ligh Liou, Vice President, Division of Regulatory Affair & Business Development, iStat Biomedical Co., Ltd., Taiwan

PLUS 4 NEW TOPICAL WORKSHOPS

A Fundamentals of R&D B The Art of Guanxi – C Fundamentals of R&D D Gaining Biosimilars
Part 1: Creating the Principles for Successful Part 2: From Concept to Approval in US
Right Environment for Business in China Commercialization – and EU
Innovation A Roadmap for Success

www.chinapharmard.com
Produced by: Bronze Sponsor: Exhibitors: Panel Sponsors: Supported by:

Life
Sciences

Media Partners:
CanBiotech
R&D Outsourcing
Capital Sourcing
International Marketing Partner:
Competitive Intelligence

REGISTER NOW! Customer Service Hotline: +65 6508 2401 / +86 21 2326 3680
 CONFERENCE DAY ONE
Tuesday 21 May 2013
08.00 Registration and Welcome Coffee
08.30 Welcome and Opening Remarks from the Chair
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, Singapore
Drug Discovery and Development Week Plenary
08.40 State of Play: Where is the Pharmaceutical Industry Heading?
• Defining the market factors which have influenced the growth or posed hindrance to the
pharmaceutical industry
• The opportunities of new markets in the midst of an economic downturn
• Managing clinical needs rather than cost in areas of terminal care where advances arises from
biologicals offering improved life expectancy
Alan Sheppard, Principal, Global Generics, Thought Leadership, IMS Health, UK
09.15 Integrative Medicine for the New Century: A US-China Perspective
• Overview of Integrative Medicine in the U.S. and in China
KEYNOTE
• Chinese healthcare system and its current development
• Peeking into the emerging role of integrative medicine in global healthcare
Ka-Kit Hui, MD, FACP, Wallis Annenberg Chair in Integrative East-West Medicine, Chair,
Collaborative Centers for Integrative Medicine, Professor, Founder & Director, Center
for East-West Medicine, Department of Medicine, UCLA, USA
09.50 Emerging Trends in Investments: Alternative Funding Models and Strategic
Portfolio Management
• How can companies be attractive to investors?
PANEL DISCUSSION
• Best practices for investors to choose the molecule to invest in
• Diversifying the investment portfolio - How much should I invest in each portfolio?
• Analyzing the biosimilars prospects and what is the true potential?
Moderator:
Simone Song, Executive Director, IBD, Goldman Sachs (Asia) L.L.C, Hong Kong
Panellists:
David G. Wang, MD, PhD, Senior Managing Director, OrbiMed Asia, China
Wu Chun, Partner and Managing Director, Boston Consulting Group, Hong Kong
Dianna Qian, Principal, FIL Capital Management, China
James Huang, Managing Partner, KPCB, China
10.35 Opening of Exhibits & Morning Refreshments
China Healthcare Policy – Impact on Innovation
Session Chair
Li Chen, President and Chief Executive Officer, Hua Medicine, China
11.05 Implications of the 12th 5 Year Plan: Multinational Perspective on the
Opportunities and Challenges for R&D in China
• Industry interpretation of the Healthcare Reform and 12th 5 year plan: What this means for
R&D and innovation
• Identifying the potential opportunities in China for domestic and multinational companies
• Recognising the key challenges for R&D in China
Dr Zheng Li, General Manager, Lundbeck Research, China
11.35 Domestic CxO Perspective on the Future of Pharma in Asia: To what Extent
is the Landscape Shifting to Support Innovation?
• Generics play an important role given the limited government investment in healthcare –
PANEL DISCUSSION
is the government willing to spend on innovator drugs?
• How will the research field in China be changing over the next decade?
• Can there be a second wave of Eastern-researched blockbusters? If not, what needs to
change?
• What is the ‘real’ impact of the $125 billion that will be spent:
~ Is there really an opportunity for the pharma industry or is the emphasis on tertiary care?
• What impact will the health insurance reform have?
Moderator:
Ming Guo, PhD, Co-Founder & Chief Operating Officer, Ascentage Pharma, and
General Manager, Small Molecule Drug R&D Center, China Medical City, China
Panellists:
Bon Chul Brian Ku, General Manager, SK Biopharm (Shanghai), China
Li Xianzhong, Deputy General Manager, Biotech Pharmaceutical Co. Ltd, China
Chen Chen, Chief Executive Officer, Sundia MediTech, China
Sally Sha, Director Business Development, Tigermed, China
12.20 Venture and Private Funding for Drug Development in China
• Overview of the Chinese companies that have been successful in gaining venture funding
• Outlining Chinese companies which are successfully capturing venture and other private
funding
• Considering what partnerships are driving drug development in Chinese companies
• Who are the innovators among the partners versus development partners?
• Contrast China with trends in the major markets
Ian Lloyd, Editorial Director, Preclinical Drug Information, Citeline, UK
REGISTER TODAY! +65 6508 2401 / +86 21 2326 3680
12.50 Networking Lunch
14.15 Pharma Fireside Chat with Dr Samantha Du, Managing Director,
Sequoia Capital, China
Moderator:
Jason Mann, Head China Healthcare Equity Research, Barclays Capital, Hong Kong
In this candid interview session, Dr Du will share her 20 years of experience in moving
from a pharma executive to an entrepreneur to an investor. You will gain an insight into
her thoughts on the future of R&D in China, the role of domestic vs global players in the
region and advice to entrepreneurs.
14.45 The Road of 11 Years from a Research Institute to a Real Pharmaceutical
Company
• Outlining the progression of a returnee-led company from a drug target discovery company
to first class 1.1 drug NDA approval
• Highlighting key challenges and lessons learned:
~ IND package preparation ~ Clinical trial management ~ NDA filing ~ Human resources,
financing and rising cost of operation
• Combining science with good business practice to receive optimal results
Dr Ying Luo, Chairman and Chief Executive Officer, Shanghai Genomics, Inc.,
Chairman, Beijing Continent Pharmaceuticals, China
Reducing Uncertainty in Your R&D
15.15 Approaches to Reduce Cost and Time to Market in Drug Discovery Programme
Presentation Hosted by Elsevier
15.45 Afternoon Refreshments
Science and Innovation Showcase
Session Chair
Frank Shen, Divisional Vice President, Data and Statistical Sciences, Global Pharmaceutical R&D,
AbbVie, USA
16.15 HCV Small Molecule Development from Bench to Clinic
• Defining an opportunity
KEYNOTE
• Identifying a differentiated development strategy
• Implementing novel approaches to antiviral development
Barry Bernstein MD, Divisional Vice President, Infectious Disease Development, Global
Pharmaceutical Research and Development, AbbVie, USA
16.45 Chipscreen’s Development of a Novel Subtype-Selective HDAC Inhibitor
Chidamide (CS055): From Bench to Bed
• Overview of the first subtype-selective HDAC inhibitor ready for NDA in peripheral T-cell
lymphoma as an orphan drug designation in China
• Describing the unique mechanism of action by enhancing cellular immunity against tumors;
mechanism-based improvement in safety profile comparing with other approved drugs
• Development strategy as single agent and combination treatments in China and USA
Zhi-Qiang Ning, MD, PhD, Co-Founder, Vice President Research & Development,
Shenzhen Chipscreen Biosciences Ltd, China
17.05 Application of Saponin – An Ingredient of Chinese Medicine - In Ovarian
Cancer Therapy
• Purification and characterization of anti-cancer saponins from herbal drug (Xanthoceras
sorbifolia)
• In-vitro and in-vivo studies of active saponins
• Chemical modification of the saponin
• Application of active saponins for ovarian cancer therapy
Pui-Kwong Chan, PhD, Professor, Department of Pharmacology, Baylor College of
Medicine, USA
17.25 Therapeutic Antibody Development Driven by Innovative Technologies
• Progress in research and technological innovation of therapeutic antibodies which aim to
revolutionize the therapy for cancer, autoimmune, and infectious diseases
• Antibody generation and design technology used to tailor antibodies beyond their natural
limits to meet the challenge of developing more specific, safe, and potent therapeutic
antibodies
Peter Peizhi Luo, Chief Executive Officer, Adagene Inc., China
17.45 New Biomarkers for Cervical Cancer Detection: Clinical Validation Trials in
Taiwan and China
• New clinical or pharmacogenetics biomarker research and development
• The co-clinical study of new biomarker in China and Taiwan
Yu-Ligh Liou, Vice President, Division of Regulatory Affair & Business Development,
iStat Biomedical Co., Ltd., Taiwan
18.05 Closing Remarks from the Chair
End of Day 1 Followed by Networking Drinks Reception
register@ibcasia.com.sg www.chinapharmard.com
 CONFERENCE DAY TWO
Wednesday 22 May 2013
08.30 Welcome and Opening Remarks from the Chair
Ming Guo, PhD, Co-Founder & Chief Operating Officer, Ascentage Pharma, and
General Manager, Small Molecule Drug R&D Center, China Medical City, China
The Role of Asia in Global Drug Development
08.40 Globalization of Innovation: Could the Growing Innovation Capacity in the
East Save the Western Drug Development Model?
• Discussing globalization of innovation and the growing role of China and India
• Assessing types of collaborative innovation models between companies in China/India
and their global counterparts & benefits that flow to respective partners
• Identifying areas of significant potential:
~ Leveraging innovation capacity in Asia for addressing prevalent diseases in the
developing world
~ Cross-border SME-SME linkages, a potent force for innovation, but yet underutilized
Rahim Rezaie, Research Fellow, Rotman School of Management, University of
Toronto and Asia Pacific Foundation of Canada (Vancouver), Canada
09.15 Horizon-Scanning: Who Will Lead Innovation in 2020?
Each panellist will provide a 10 minute overview of innovation landscape in their region
(China, India, Rest of Asia), followed by a candid discussion about the future of innovation
PANEL DISCUSSION
• Comparing and contrasting R&D policy, strategy and government support
• Hypothesizing where each of these countries will be in 2020, and where your investment
will be justified
• Predicting where the majority of innovation will come from in 2020 – The West/China/
India/Rest of Asia
Moderator:
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, Singapore
Panellists:
Yajiong Xue, PhD, Director, Center for Healthcare Management Systems, Associate
Professor of MIS, College of Business, East Carolina University, USA
James Garner, MD, Vice President and General Manager, Takeda Global Research
and Development Center (Asia), Singapore
Rahim Rezaie, Research Fellow, Rotman School of Management, University of
Toronto and Asia Pacific Foundation of Canada (Vancouver), Canada
10.15 Morning Refreshments
11.00 How to be Successful in Bringing Innovative Products to China
• Discussing strategies for international companies to successfully bring a product to China
STRATEGIZING DISCUSSION
• Addressing key questions:
• Do you partner with a domestic company or enter alone?
• Do you repeat phase 1-3 clinical studies or skip this phase?
• Assessing the role of domestic companies and scope for future partnership opportunities
Moderator:
Jun Bao, Director of Worldwide Business Development, GlaxoSmithKline, China
Panellists:
Cezary Statuch MD, Vice President, Head of China Research & Development,
Bristol-Myers Squibb, China
Dr Zheng Li, General Manager, Lundbeck Research, China
Frank Shen, Divisional Vice President, Data and Statistical Sciences, Global
Pharmaceutical R&D, AbbVie, USA
Zhihao Yu, Analyst, Lux Research Inc., China
11.45 Pharma Fireside Chat with Li Chen, Chief Executive Officer, Hua Medicine, China
Moderator:
Ian Haydock, Asia Editor, SCRIP Intelligence, Japan
In this ‘tell-all’ interview, Dr Chen will share his personal experiences as an R&D leader
in both USA and China. Discussing the key differences in attitude and infrastructure,
how he has seen the landscape for R&D in China change and predicts where it’s
heading in the future.
12.15 Spotlight Session
Raise your corporate profile by sponsoring or exhibiting at IBC’s 8th International
China Pharmaceutical R&D Summit. For details on speaking in this session or
other sponsorship opportunities, please contact Yvonne Leong: Tel: +65 6508 2489;
Email: Yvonne.Leong@ibcasia.com.sg
12.45 Networking Lunch
REGISTER TODAY! +65 6508 2401 / +86 21 2326 3680
Session Chair
Rahim Rezaie, Research Fellow, Rotman School of Management, University of Toronto and
Asia Pacific Foundation of Canada (Vancouver), Canada
Emerging Business Models: R&D Partnerships Between East and West
13.45 Ironwood and AstraZeneca Partnership
In this insightful interview you will have the opportunity to hear from both sides of the partnership,
KEYNOTE
learning about the strategies behind the business decisions, key challenges, successes and vision
for the future of the collaboration.
Moderator:
Betty Su, Vice President, Boston Healthcare Associates, China
Panellists:
Jim O’Mara, Vice President Corporate Development, Ironwood Pharmaceuticals,
USA
Augustine Yee, Head of Asia Pacific Corporate and Regional Development and China
Vice President of Business Development, AstraZeneca, China
14.30 NeuroVive Pharmaceutical and Sihuan Pharmaceutical Collaboration Drug
Development Strategies for Evolving Marketplaces: Reinventing Biopharma
through Strategic Alliances
• Defining criteria for successful partnership
• Strategies to cope with culture differences
• Challenges in harmonizing clinical trials and regulatory affairs in conducting international
clinical trial programs
• How to build long-term success and a sustainable business
Mikael Brönnegård, MD, PhD, Associate Professor and Chief Executive Officer,
NeuroVive Pharmaceutical AB, Sweden
15.05 Start-ups, SMEs and China: Large Gains for Niche Players
• Real experience on successful partnerships between start-ups and SMEs in China
• Share and understand how to evaluate product potential from a China point of view
• Building on proven science to create innovative niche product opportunities in China's
vast market
Robert Braithwaite, Chief Executive Officer, Luqa Pharmaceuticals, China
15.40 Afternoon Refreshments
16.10 Assessing the Co-Development Partnering Model between East and West:
A Recipe for Success or Failure?
• Outlining the key challenges in a co-development collaboration
PANEL DISCUSSION
• Strategies to ensure success in a co-development partnering model
• Highlighting the benefits and risks for each party
• Discussing the impact of a co-development partnering model on innovation on a
global scale
• Opportunities vs risks: Is this a sustainable partnering model for the future?
Moderator:
Yariv Hefez, Vice President, Business Development and Alliance Management,
Biosimilars, Merck Serono, Switzerland
Panellists:
Binhui (Ben) Ni, Head of Scouting & Partnership, Sanofi Aventis, China
Robert Chen, Senior Director, Global Strategy & Partnering, Genor Biopharma,
China
Zhi-Qiang Ning, MD, PhD, Co-Founder, Vice President Research & Development,
Shenzhen Chipscreen Biosciences Ltd, China
Jim O’Mara, Vice President Corporate Development, Ironwood Pharmaceuticals,
USA
Zhen Zhang, Associate Director, Analytical and Bioanalytical Development,
Bristol-Myers Squibb, China
The Future of Medicine and Direction of R&D
16.55 Translating Innovation to the Market
• How to strengthen collaborations between academia, clinical research institutes, pharma
CLOSING VISIONARY PANEL DISCUSSION
and biotech industry to achieve cost effective delivery of affordable medicines to the
general population
• What is the future for integrating medicine between the East and West?
• What is the role and benefits of translational medicine to enhance R&D?
• Current situation of Orphan Drugs development in China and future policy & investment
environment?
• Development of novel biologics and home-grown biobetters in China for treating
complicated diseases
Moderator:
Prof. Aamir Shahzad, MD, Director of Administration, International Society
for Translational Medicine (ISTM), Austria
Panellists:
Guoqing Cao, Vice President of Biology, Jiangsu Hengrui Medicine, China
Jimmy Zhang, PhD, Managing Director, MSD Early Investments – Greater China,
Merck & Co., Inc., China
Ka-Kit Hui, MD, FACP, Professor, Founder & Director, Center for East-West
Medicine, Department of Medicine, UCLA, USA
Peter Peizhi Luo, Chief Executive Officer, Adagene Inc., China
17.40 Closing Remarks from the Chair & End of Conference
register@ibcasia.com.sg www.chinapharmard.com
 WORKSHOPS
PRE-CONFERENCE WORKSHOPS: POST-CONFERENCE WORKSHOPS:
Monday | 20 May 2013 Thursday | 23 May 2013
Registration begins 30 minutes prior to each workshop. Half-day workshops include a refreshment break and lunch is catered for delegates attending a full day ie morning + afternoon workshop.

A Fundamentals of R&D Part 1: Creating C Fundamentals of R&D Part 2: From Concept

the Right Environment for Innovation
Led by: Al Dampier, Chief Executive Officer, Dampier Consulting Group LLC, USA
A focus on innovative R&D is essential for companies in China to remain competitive
in the market and to take advantage of the government’s investment in innovation.
This workshop is designed for prospective innovator companies and established
09.00 – 12.30
to Commercialization – A Roadmap for Success
Led by: Al Dampier, Chief Executive Officer, Dampier Consulting Group LLC, USA
A staggering number of start-ups fail within the first three years. Understanding the stages
of the drug development process, the decisions and the risks of each stage in the process is
vital to give your pharma start-up a chance.

generic companies moving to an innovator model.
Topics of discussion will include:
• Organizational structures and practices that promote innovation
• Barriers to innovation
• How to develop skills, capabilities and attitudes conducive to innovation
• An experiential exercise to get you thinking in an innovative manner
• Moving from an ‘imitation to innovation’ mindset
• Creativity and change management models
• Sustainable change
• Leading innovation and change
This workshop is designed to provide start-ups and entrepreneurs with an overview of the
skills and resources required to take your NCE/NBE from concept to commercialization. From
a meaningful business and risk management plan, to a product launch and post-market
strategy, this workshop will advise on how to avoid unnecessary costs and risks, and is a must
for all new start-up leaders.
In this participative workshop, you will switch your hat from a scientist to a business person.
You have a great idea or a great product, but that's not enough. What does it take to
commercialize a product?
Topics of discussion will include:
• The Business Plan
• Creating a Strategic Framework for Growth
• Demystify VC and Angel Networks
• Hiring a Team – Who do you need on your team to be successful

B The Art of Guanxi – Principles D Gaining Biosimilars Approval in US and EU

for Successful Business in China Led by: Dr Anita O’Connor, Managing Partner, Anita O’Connor Consulting, USA
Led by: Seth Goldenberg, Senior Principal Scientist, NAMSA, USA
Angela Luo, Senior Partner, Beijing Long An Law Firm Shanghai Workshop Objectives:
Branch, China To provide an overview of the regulatory requirements for marketing approval of biosimilars
14.00 – 17.30

The success of your business in China is significantly dependent on your personal in the US and EU, along with the challenges that sponsors face in developing a biosimilar.
relationships and careful planning at the beginning to meet your long-term goals.
Your ability to maintain successful partnerships, develop a balanced market entry Workshop Agenda:
plan, and overall success in China will depend on your understanding of the cross- • Introduction to biosimilars
cultural differences and unique legal and regulatory framework. • Analytical and functional studies recommended by EU and US regulatory authorities
This workshop will provide critical insights on: • Animal studies to include pharmacodynamic, pharmacokinetic and toxicology studies
• How to do business locally • Clinical trials for biosimilars to include pharmacovigilance
• How to setup the right business structure to meet your goals
• How to expand your company in the region
• How to attract and retain the right staff
• How to build commercial and distribution channels

WHO YOU WILL MEET AT DRUG DISCOVERY AND DEVELOPMENT WEEK 2013
By Industry: By Country: By Job Function:
Originators 35% Generics & China 40% Rest of North R&D/Innovation Strategy/
Biosimilars 30% Asia 15% 20% Commercialisation/
Licensing 15%
Sales and
Marketing
Business 10%
SE Asia Development
5% 15%

Biotech USA 10% Regulatory 5% Clinical

10% Academic 5%
Europe Academia 5%
10% Rest of World 5% 10%
Legal 10%
India 15% Biomanufacturing 15% Legal 10%
Solution Providers 5%

PROMOTIONAL OPPORTUNITIES: SPEAK • SPONSOR • EXHIBIT • NETWORK

• • •
Use IBC’s Drug Discovery and Development Week to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience.
Gain access to 300+ key decision-makers from local, regional and multinational pharma and biotech companies.
We are able to tailor a sponsorship solution to your needs. To find out more please contact Yvonne Leong, T: +65 6508 2489 E: Yvonne.Leong@ibcasia.com.sg

2013 Sponsors:

REGISTER TODAY! +65 6508 2401 / +86 21 2326 3680 register@ibcasia.com.sg www.chinapharmard.com
Harnessing the Best of East and West to Fuel Drug Development
Part of:
Now in its 8th year, IBC’s China Pharmaceutical R&D
Summit continues to be a leading industry gathering,
reputed for its quality content, high-caliber speaker
panel and invaluable networking opportunities. IBC Life Sciences’ Drug Discovery & Development Week brings
together international and regional decision makers to address
Featuring 100+ attendees, 35+ topic experts, 20+ hours the industry’s most pressing concerns. Whether from
of structured and informal networking over 4 days, plus innovators in pharmaceutical R&D to developers of biologics
a comprehensive agenda covering the policy, regulatory, and biosimilars, this is China’s most targeted world class
legal and funding environment in China and the future forum providing the latest strategies, expertise, technologies
of pharmaceuticals globally. If you can only attend one and solutions.
China R&D and partnering event in 2013, make it IBC’s Co-located With:
China Pharmaceutical R&D Summit!

Who Should Attend:

• CEO/CSO/COO/VP from Domestic Chinese Companies
• VP/Head/Group Leader of R&D, Drug Discovery, External Collaboration, Business Development from International
SME and MNC Pharma and Biotech IBC’s 4th Annual Biosimilars Asia is the region’s largest
gathering of leading and future stakeholders. Lively debates,
• Professor/Head of Department from Academic and Research Institutions insightful case studies and in-depth market analysis provide
• Business Development/Sales and Marketing Executive from CROs, CMOs, Drug Discovery Research Services, maximum learning. Highlighting the latest in biosimilars
Laboratory Services development, commercial strategies and know-how in
biomanufacturing to bring affordable medicines to market.
www.biosimilarsasia.com
Register & Pay by 8 March to save up to US$300 / CNY1,000 each

Developing Market Share & Asset Protection in Emerging Market Frameworks

21 – 23 MAY 2013 | GRAND HYATT SHANGHAI, CHINA

IBC’s 2nd Pharma Legal Affairs Asia features a distinguished

speaker faculty of pharmaceutical and biotech counsel coupled
with legal experts. It provides a unique forum for dealmakers
and legal minds to address the industry’s most compelling and
current legal issues.
www.pharmalegalasia.com

Drug Discovery and Development Week: Programme at a Glance

CHINA PHARMA BIOSIMILARS: PHARMA LEGAL
BIOSIMILARS: STRATEGY
R&D SUMMIT BIOMANUFACTURING AFFAIRS ASIA
Monday PRE-CONFERENCE WORKSHOPS
20 May 2013 A: Fundamentals of R&D Part 1: Creating the Right Environment for Innovation
B: The Art of Guanxi – Principles for Successful Business in China
CONFERENCE DAY 1
China Pharma R&D and Biosimilars Joint Plenary Session: The Global Pharmaceutical Landscape
Regional Legal Framework Update
China Healthcare Policy – Impact on Innovation Biosimilars Plenary: Successful Navigation of the Evolving Biosimilars Landscape
Tuesday
21 May 2013 JOINT NETWORKING LUNCHEON
Product Development & New Market Expansion Preparations Before Embarking on
Science and Innovation Showcase Biomanufacturing IP Loss Prevention and Enforcement
Risk & Returns to Consider Before Entry
SPONSORED EVENING COCKTAIL RECEPTION
CONFERENCE DAY 2
Biosimilars Plenary: Global Regulatory Guidelines Overview
The Role of Asia in Global Drug Development Strategic Collaborations to Strengthen Legal Issues in Pharma Commercial Contracts
Wednesday Increasing Cost Efficiencies
Value Chain
22 May 2013
JOINT NETWORKING LUNCHEON
R&D Partnerships Between East and West
Developing Sustainable Competitive Strategies Successful Scaling up Conditions Compliance With Latest Pharma Legislation
The Future of Medicine and Direction of R&D

Thursday POST-CONFERENCE WORKSHOPS

23 May 2013 C: Fundamentals of R&D Part 2: From Concept to Commercialization – A Roadmap for Success
D: Gaining Biosimilars Approval in US and EU

REGISTER TODAY! +65 6508 2401 / +86 21 2326 3680 register@ibcasia.com.sg www.chinapharmard.com
If undelivered, please return to:
“Looks like two really packed
111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
days. Should be great!”
Tel: +65 6508 2400 Fax: +65 6508 2408 ~ 2013 Speaker

8th International China Pharmaceutical R&D Summit

ENJOY SUBSTANTIAL SAVINGS WITH
OUR MULTIPLE BOOKING DISCOUNT!
6 EASY WAYS TO REGISTER
MAIL the attached registration form with your Scan the QR Code
cheque to IBC Asia (S) Pte Ltd with your smartphone
c/o Informa Regional Business Services and register today
111 Somerset Road, TripleOne Somerset
#10-06, Singapore 238164

Customer Service Hotline

Fax
+65 6508 2401 [Singapore]
+65 6508 2407
+86 21 2326 3680 [China]
This label contains your priority booking code. To expedite registration, please do not remove label. If you have Email Web
already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not
available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop. register@ibcasia.com.sg www.chinapharmard.com

RESERVE YOUR PLACE TODAY! HOTEL INFORMATION

Grand Hyatt Shanghai, China
❑ Yes! I/We will attend the 8th International China Pharmaceutical R&D Summit ❑ I would like to purchase the conference presentations Jin Mao Tower, 88 Century Boulevard,
20 – 23 May 2013, Grand Hyatt Shanghai, China at SGD1000 + GST (SGD1070) per log in.
Pudong, Shanghai 200121
International Companies – International Early Bird Rate Special Rate Normal Rate Group Rate Tel: +86 21 5049 1234 | Fax: +68 21 5049 8381
companies are ones with Global Headquarters Register & pay on or Register & pay on or Register & pay after (3 or more delegates) Contact Person: Lisa Sun
located outside mainland China before 8 Mar 2013 before 12 Apr 2013 12 Apr 2013
Email: lisa.sun@hyatt.com
❑ 4 Day Pass – Conference + All Workshops USD2,695 USD2,895 USD2,995 USD2,495
❑ 3.5 Day Pass – Conference + 3 Workshops PAYMENT TERMS
USD2,495 USD2,695 USD2,795 USD2,295
❑A ❑B ❑C ❑D Payment must be received 10 business days prior to the event.
❑ 3 Day Pass – Conference + 2 Workshops USD2,295 USD2,495 USD2,595 USD2,095 To take advantage of discounts with an expiry cut-off date,
❑A ❑B ❑C ❑D registration and payment must be received by the cut-off date.
❑ 2.5 Day Pass – Conference + 1 Workshop USD1,995 USD2,195 USD2,295 USD1,795
All payments should be made in US or CNY dollars.
❑A ❑B ❑C ❑D • Payments by US$ bank draft or cheque should be made in
favour of “IBC Asia (S) Pte Ltd” and mailed to:
❑ 2 Day Package – Conference only USD1,695 USD1,895 USD1,995 USD1,495
IBC Asia (S) Pte Ltd
China Domestic Companies – A China domestic company has its global headquarters located within mainland China c/o Informa Regional Business Services
❑ 4 Day Pass – Conference + All Workshops CNY7,000 CNY7,500 CNY8,000 CNY6,500 111 Somerset Road, TripleOne Somerset #10-06,
Singapore 238164
❑ 3.5 Day Pass – Conference + 3 Workshops
CNY6,500 CNY7,000 CNY7,500 CNY6,000 Attn: The Accounts Receivable Team
❑A ❑B ❑C ❑D • Payment by telegraphic transfer in US$ must be made to:
❑ 3 Day Pass – Conference + 2 Workshops
CNY6,000 CNY6,500 CNY7,000 CNY5,500 IBC Asia (S) Pte Ltd
❑A ❑B ❑C ❑D A/C No.: 260-457866-178 (USD)
❑ 2.5 Day Pass – Conference + 1 Workshop
CNY5,500 CNY6,000 CNY6,500 CNY5,000
The Hongkong and Shanghai Banking Corporation Limited,
❑A ❑B ❑C ❑D 21 Collyer Quay, HSBC Building, Singapore 049320
Bank Swift Code: HSBCSGSG
❑ 2 Day Package – Conference only CNY5,000 CNY5,500 CNY6,000 CNY4,500
Bank Code: 7232
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time. Fee stated
is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate. • Payment by telegraphic transfer in CNY must be made to:
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel. A/C Name: IBC
• Registration fees are subject to the prevailing government tax.
• 3.5% VAT is applicable to all companies paying in CNY. Conferences and Event Management Services (Shanghai)
• Regulatory Authorities, Government and Academia will be accorded 40% off Normal Rates.
Co., Ltd.
Delegate 1 Details Delegate 2 Details A/C No.: 720-031103-001
Name: Dr/Mr/Ms Name: Dr/Mr/Ms Beneficiary Bank: HSBC
Job Title: Job Title: Bank (China) Company Limited
Department Department Bank Address: No. 1000 Lujiazui Rind Road, Pudong, Shanghai
Tel: Tel: 200120, P.R. China
• Payment by credit card in US$ (AMEX, VISA or MasterCard)
Mobile No.: Mobile No.:
The best way to pay by credit card is through our secure portal
Email: Email: built into the website. To pay by phone please indicate the
Delegate 3 Details Delegate 4 Details contact name and details below and our Customer Services

T
Team will call within 24 hours to take payment. Please do not

UN
Name: Dr/Mr/Ms Name: Dr/Mr/Ms
send credit card information by email.
O
Job Title: Job Title:

ISC
CANCELLATION / SUBSTITUTION
E
FRE
Department Department
Tel:
PD Tel: Should you be unable to attend, a substitute delegate is welcome
OU at no extra charge. Cancellations must be received in writing at
GR
Mobile No.: Mobile No.:
Email: Email: least 10 business days before the start of the event, to receive a
Please photocopy for additional delegates refund less 10% processing fee per registration. The company
regrets that no refund will be made available for cancellation
Who is Head of your Department? notifications received less than 10 business days before the event.
Who is Head of Training?
IMPORTANT NOTE
Company Information
Please quote the name of the delegate, event title and invoice
Company Name: Main Business/Activity: number on the advice when remitting payment. Bank charges are
Address: Postal Code: to be deducted from participating organisations own accounts.
Please fax your payment details (copy of remittance advice, cheque
Payment Method (Please tick:) ❑ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd or draft to +65 6508 2407).
❑ I am paying by bank transfer (copy attached) Attendance will only be permitted upon receipt of full payment.
❑ Payment by Credit Card. (AMEX, VISA or MasterCard accepted) Participants wishing to register at the door are responsible to ensure
CREDIT CARD PAYMENTS all details are as published. IBC assumes no further liability or
obligation, beyond the refund of the paid registration fee, in the
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at www.chinapharmard.com event of postponement or cancellation by IBC.
and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name and details and our Customer
Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest confidence, please do not DATA PROTECTION
send payment details by email. The personal information entered during your registration/order, or
REG NO. 200108203N

provided by you, will be held on a database and may be shared

Credit card contact: Department: with companies in the Informa Group in the UK and internationally.
Occasionally, your details may be obtained from or shared with
Direct phone number: Email: external companies who wish to communicate with you offers
related to your business activities. If you do not wish your details
P46219 web to be used for this purpose, please contact our Database Department
at Email: database@ibcasia.com.sg, Tel: +65 6508 2400 or
REGISTER NOW! FAX BACK TO +65 6508 2407 Fax: +65 6508 2408.